These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2558424)

  • 1. Influence of a low molecular weight heparin on the inhibition of factor Xa and thrombin in hip surgery.
    Mätzsch T; Bergqvist D; Fredin H; Hedner U; Ostergaard P
    Thromb Res; 1989 Nov; 56(4):559-64. PubMed ID: 2558424
    [No Abstract]   [Full Text] [Related]  

  • 2. Low molecular weight heparin-catalyzed inactivation of factor Xa and thrombin by antithrombin III--effect of platelet factor 4.
    Schoen P; Lindhout T; Franssen J; Hemker HC
    Thromb Haemost; 1991 Oct; 66(4):435-41. PubMed ID: 1665594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ratios of anti-factor Xa to antithrombin activities of heparins as determined in recalcified human plasma.
    Schoen P; Lindhout T; Hemker HC
    Br J Haematol; 1992 Jun; 81(2):255-62. PubMed ID: 1322691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactically equivalent doses of Enoxaparin and unfractionated heparin inhibit in vivo coagulation to the same extent.
    Ofosu FA; Levine M; Craven S; Dewar L; Shafai S; Blajchman MA
    Br J Haematol; 1992 Oct; 82(2):400-5. PubMed ID: 1329920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a heparan sulphate with high affinity for antithrombin III upon inactivation of thrombin and coagulation factor Xa.
    Scully MF; Ellis V; Shah N; Kakkar V
    Biochem J; 1989 Sep; 262(2):651-8. PubMed ID: 2529852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
    Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
    Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
    Hainer JW; Sherrard DJ; Swan SK; Barrett JS; Assaid CA; Fossler MJ; Cox DS; Williams RM; Pittenger AL; Stephenson CA; Hua TA
    Am J Kidney Dis; 2002 Sep; 40(3):531-8. PubMed ID: 12200805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low molecular weight heparin in hemodialysis patients with a bleeding tendency.
    Leu JG; Chiang SS; Lin SM; Pai JK; Jiang WW
    Nephron; 2000 Dec; 86(4):499-501. PubMed ID: 11124600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of action of low molecular weight heparins and heparinoids.
    Ofosu FA; Barrowcliffe TW
    Baillieres Clin Haematol; 1990 Jul; 3(3):505-29. PubMed ID: 1703023
    [No Abstract]   [Full Text] [Related]  

  • 11. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
    Lu X; Lin J
    BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty.
    Kim SM; Moon YW; Lim SJ; Kim DW; Park YS
    Thromb Haemost; 2016 Mar; 115(3):600-7. PubMed ID: 26790579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [D-dimer, thrombin-antithrombin III-complex (TAT) and prothrombin fragment 1+2 (PTF). Parameters for monitoring therapy with low molecular-weight heparin in coagulation disorders].
    Hofmann M; Rest A; Hafner G; Tanner B; Brockerhoff P; Weilemann LS
    Anaesthesist; 1997 Aug; 46(8):689-96. PubMed ID: 9382207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II, and antithrombin III affinity between low molecular weight heparin and unfractionated heparin.
    Shimotori T; Sakuragawa N
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():71-6. PubMed ID: 1962909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage.
    Leizorovicz A; Bara L; Samama MM; Haugh MC
    Haemostasis; 1993 Mar; 23 Suppl 1():89-98. PubMed ID: 8388357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of anticoagulant mechanism of low molecular weight heparin.
    Hamano S; Nishiyama M; Komatsu H; Miyata H; Ikeda S; Sakuragawa N
    Thromb Res; 1992 Mar; 65(6):801-8. PubMed ID: 1321995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro--modulatory action of glycosaminoglycans.
    Kaiser B; Hoppensteadt DA; Jeske W; Wun TC; Fareed J
    Thromb Res; 1994 Sep; 75(6):609-16. PubMed ID: 7831680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4).
    Padilla A; Gray E; Pepper DS; Barrowcliffe TW
    Br J Haematol; 1992 Oct; 82(2):406-13. PubMed ID: 1329921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.